Although many correlations between different genetic variants and PCa clinical outcomes are yet to be revealed, patients with pathogenic variants in DNA damage repair genes, especially those from homologous recombinant repair (HRR) such as ATM, BRCA2, and BRCA1, are found to be closely associated with younger onset, increased risks, and poorer prognosis (8, 9). This evidence concerns the gene BRCA2 and posterior cortical atrophy.